A policy-analytic and normative ethical study published in Philosophy, Ethics, and Humanities in Medicine by researcher Long Chen evaluates the legislative recognition and operational challenges of living wills in China following landmark legal reforms in Shenzhen. In June 2022, the revised Medical Regulations of Shenzhen Special Economic Zone established mainland China’s inaugural statutory mechanism recognizing advance directives as legally binding instruments, marking a historic turning point for patient self-determination. However, the study demonstrates that integrating living wills into clinical practice faces profound ethical, cultural, professional, and institutional resistance. To overcome these barriers and protect the fundamental rights and dignity of terminally ill patients, the author proposes a tripartite implementation framework focused on death literacy education, procedural legal refinement, and a national hospice safeguard system. Because this study is a policy analysis synthesizing existing literature, demographic data, and legal texts without primary empirical surveys, it focuses on resolving systemic structural barriers across legal and healthcare domains.
The critical demand for advance medical decision-making in China unfolds against an unprecedented demographic transition marked by rapid population aging. According to data from the National Bureau of Statistics cited in the research, mainland China’s populace aged sixty and older reached 296.97 million individuals by the end of 2023, constituting 21.1 percent of the national population after an annual increase exceeding sixteen million older adults. The Blue Book of Healthy Aging Development in China projects that this demographic will peak at 487 million people, or 34.9 percent of the total population, by 2050, with individuals aged eighty and older expanding to 150 million. In parallel, epidemiological transitions have intensified clinical demand; the 2023 China Health Statistics Yearbook reports that malignant tumors represented the second leading cause of disease in urban regions at 24.61 percent and third in rural areas at 22.47 percent in 2021. While population aging frames this demographic reality, living wills specifically target terminally ill patients confronting end-of-life care.
Conceptually, the study defines a living will as a legally binding document through which mentally competent individuals predefine their preferences for or refusal of life-sustaining treatments upon facing terminal illness or irreversible incapacity. The term originally appeared in a 1969 Indiana Law Journal article framing advance directives as a due process mechanism for euthanasia, asserting that individuals retain the right to govern medical choices just as they prearrange property distribution. Unlike testamentary wills, living wills direct personal autonomy over medical interventions such as intubation and chemotherapy before biological death occurs. In mainland China, civil society advocacy commenced in 2006 through the Choice and Dignity platform initiated by medical experts led by Luo Yuping. This advocacy yielded the 2011 civil instrument My Five Wishes, enabling registrants to establish treatment preferences, dignity protocols, kin communication, and surrogate decision-makers, attracting over 50,000 registered participants and 21,618 completed declarations by 2020.
The clinical adoption of advance directives provokes profound ethical disputes regarding personal autonomy, collective welfare, and constitutional protections of life. Proponents assert that living wills embody vital respect for individual self-determination, conceptualizing death as an intrinsic phase of life requiring affirmative legal guardianship. From this perspective, legally permitting suicide while condemning autonomous treatment refusal at the end of life represents an ethical contradiction. Conversely, critics emphasize that human existence involves inescapable social responsibilities to family and community, arguing that unilateral choices to terminate treatment violate collective obligations. The policy analysis maintains that the central constitutional principle at stake is safeguarding life’s dignity throughout its continuum from birth to death. Regulatory mechanisms must therefore prevent the instrumentalization of living wills, exclude non-authentic motives such as familial coercion or financial expediency, and guarantee that clinical protocols center strictly on preserving the moral and legal sanctity of human life.
The study further contrasts Chinese statutory definitions of dignity with Western theological doctrines that influence global bioethics. In Western Christian traditions, human life is viewed as a divine gift possessing intrinsic sanctity under the doctrine of imago Dei, regarding treatment refusal as an unacceptable transgression against sacred creation principles. In contrast, mainland China’s secular legal architecture safeguards personal dignity through enforceable personality interests that persist postmortem. For example, Article 994 of the Civil Code prohibits postmortem violations of a deceased individual’s name, portrait, reputation, or bodily remains, while Article 302 of the Criminal Code penalizes corpse desecration. Additionally, Article 990 of the Civil Code protects concrete rights including life, bodily integrity, and health, alongside abstract interests grounded in personal freedom. Operating independently of religious dogmas, the Chinese legal framework requires living will mechanisms to align with fundamental personality rights while establishing robust procedural guarantees for validity, authentic intent, and revocation.
Despite statutory autonomy, medical self-determination encounters severe practical barriers involving clinical decision-making capacity and shifting patient preferences. While scholarship affirms the right to therapeutic refusal as a vital component of informed consent, clinical reality reveals that preferences often fluctuate across disease trajectories. The study highlights documented shifts in the will-to-live among cancer patients as physiological distress and interpersonal dynamics change over time. Furthermore, profound information asymmetries between clinicians and patients complicate the capacity to evaluate complex interventions rationally, heightening susceptibility to external familial pressure or financial coercion. Implementation becomes even more contentious when an advance directive contradicts the emotional desires of family members or the therapeutic judgments of physicians. These dilemmas intensify because primary living will signatories are typically advanced-stage patients experiencing coma or impaired consciousness, leaving healthcare teams without reliable mechanisms to verify whether a pre-signed document authentically reflects the patient’s immediate intent.
Societal acceptance of living wills in China is deeply challenged by traditional Confucian ethical norms that govern familial relationships. Cultural scholar Liang Shuming noted that traditional China developed as an ethic-based society centered on patriarchal clans and moral codes, crystallized in the three cardinal guides and five constant virtues. Sociologist Fei Xiaotong similarly described traditional China as a society ruled by courtesy, where etiquette norms were embedded in statutory codes across dynasties, including the Duke of Zhou Rites, the Jin Dynasty’s Mourning Apparel System, and the Tang Dynasty’s Ten Abominations. Within this moral tradition, filial piety, or xiao, occupies the foremost position, obligating adult children to serve their parents diligently and pursue all medical avenues during illness. Consequently, forgoing treatment before a parent has completely lost vital signs is widely perceived as an intolerable violation of filial duty, creating substantial cultural resistance against advance directives.
Medical professional ethics creates additional tension with the clinical execution of living wills. Foundational codes, including the Hippocratic Oath and the World Medical Association’s 1948 Declaration of Geneva, prioritize saving lives, seeking patient health, and doing no harm. Clinicians often feel that withholding life-sustaining interventions conflicts with their duty to preserve life, while fearing that non-intervention could inflame fragile doctor-patient relationships in China. Internationally, jurisdictions have established structured statutory frameworks to govern these conflicts, including California’s 1976 Natural Death Act, the United States 1991 Patient Self-Determination Act, and Taiwan’s 2000 Hospice and Palliative Care Act, alongside legislation in Canada, France, Japan, and Singapore. In mainland China, civil promotion advanced in 2013 when experts led by Luo Diandian established the Beijing Living Will Promotion Association, yet statutory recognition was absent until the Shenzhen Special Economic Zone Medical Regulations were revised in June 2022.
Although Article 78 of Shenzhen’s revised regulations marked China’s first legislative acknowledgment of living wills, the provision remains principle-based and lacks detailed procedural rules. Article 78 requires written or audio-visual directives specifying intentions regarding traumatic rescue and life support, attested by two uninvolved witnesses or a notary. However, it leaves critical questions unaddressed, including applicant eligibility, third-party entrustment, clinical criteria for terminal illness, familial consultation, and statutory liability protections for clinicians. To resolve these ambiguities, the study recommends establishing a national framework restricting eligibility to adults with full civil capacity under Civil Code Articles 17 to 22, paralleling South Korea’s Life-Sustaining Medical Decision Act age requirement of nineteen. Directives should require written execution, with audio-visual options permitted only for incapacitated writers witnessed by two individuals, including a physician. Centralized registry filing, unrestricted revocation rights, two-physician terminal certification, and good-faith statutory immunity for healthcare institutions are essential safeguards.
Finally, the implementation of living wills depends upon remedying severe systemic deficits in China’s hospice and palliative care infrastructure. Declining life-prolonging treatments is intended to transition patients to holistic palliative care rather than clinical abandonment; however, China faces an acute shortage exceeding 120,000 trained palliative professionals against international staffing standards. Palliative resources are also skewed, with eastern China containing 63 percent of facilities, compounded by fragmented medical insurance financing. Although policy guidelines have emerged since 2017—including the Basic Standards for Hospice Care Centers and the Basic Medical and Health Promotion Law—systemic capacity remains inadequate. Drawing on international models, including the United Kingdom’s National Health Service Gold Standards Framework, American Medicare reimbursement, and Japan’s Long-Term Care Insurance, China must expand professional training, balance regional allocation, and integrate hospice care into compulsory medical insurance. The author emphasizes public death literacy—citing a survey of 260 elderly inpatients showing deficient knowledge—while noting that future empirical research must evaluate patient perspectives directly.
Subject of Research: Ethical and practical implementation challenges of living wills and hospice care in China
Article Title: Legislative recognition and implementation challenges of living wills in China
Article References: Chen, L. (2026). Legislative recognition and implementation challenges of living wills in China. Philosophy, Ethics, and Humanities in Medicine, 21(1), Article 1. https://doi.org/10.1186/s13010-025-00208-9
Image Credits: AI Generated
DOI: 10.1186/s13010-025-00208-9
Keywords: living wills, Shenzhen Medical Regulations, advance medical directives, hospice care, palliative care, end-of-life autonomy, filial piety, medical ethics, patient self-determination, population aging in China, terminal illness, My Five Wishes, death literacy, Civil Code of China, healthcare workforce shortage, medical insurance integration, informed consent
News Source: Ophelia Keating. (November 21, 2026). Policy Analysis Examines China’s Living Will Recognition and Hospice Implementation Barriers. Scienmag.



